Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corpor...(50 percent were achieved in 78 percent o...),Health

Date:3/16/2009

50 percent were achieved in 78 percent of evaluable patients who received the picoplatin combination. In addition, interim analysis revealed that the median time to PSA progression was 8.5 months with the picoplatin combination. In this study, patients were treated with picoplatin therapy for up to 10 cycles and up to a picoplatin cumulative dose of 1200 mg. Safety results continued to demonstrate that picoplatin can be safely administered with full doses of docetaxel and prednisone, the standard treatment for metastatic CRPC, supporting the use of this combination in future clinical trials.

• Colorectal Cancer: In January 2009, the Company presented interim efficacy and safety data from its ongoing, randomized, controlled Phase 2 clinical trial of picoplatin in combination with 5-fluorouracil and leucovorin (FOLPI) in patients with metastatic colorectal cancer (CRC) at the ASCO 2009 Gastrointestinal Cancers Symposium. Results continued to show that picoplatin, given once every four weeks in the FOLPI regimen, was associated with less frequent and less severe neurotoxicity than the FOLFOX (5-fluorouracil, leucovorin and oxaliplatin) regimen, where oxaliplatin has shown treatment-limiting neurotoxicity. Results also continue to indicate that both FOLPI and FOLFOX regimens have similar anti-tumor activity as a first-line treatment for metastatic CRC, supporting the potential use of picoplatin as a neuropathy-sparing alternative to oxaliplatin.

• Oral Picoplatin: In November, the Company announced top-line results from a Phase 1 clinical trial of an oral formulation of picoplatin in patients with solid tumors. These results indicated that picoplatin achieves linear and dose-dependent plasma exposure when given by the oral route, indicating sufficient bioavailability to support further clinical development of an oral formulation of the drug.
  '/>"/>

SOURCE Poniard Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial